NASDAQ:ATRC - AtriCure Stock Price, Price Target & More

$21.21 -0.12 (-0.56 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$21.21
Today's Range$21.13 - $21.54
52-Week Range$14.88 - $25.18
Volume93,213 shs
Average Volume209,961 shs
Market Capitalization$748.19 million
P/E Ratio-25.55
Dividend YieldN/A
Beta0.26

About AtriCure (NASDAQ:ATRC)

AtriCure logoAtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. AtriCure sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.

Receive ATRC News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ATRC
CUSIP04963C20
Phone513-755-4100

Debt

Debt-to-Equity Ratio0.23%
Current Ratio2.58%
Quick Ratio1.87%

Price-To-Earnings

Trailing P/E Ratio-25.55
Forward P/E Ratio-25.55
P/E GrowthN/A

Sales & Book Value

Annual Sales$174.72 million
Price / Sales4.26
Cash FlowN/A
Price / CashN/A
Book Value$4.67 per share
Price / Book4.54

Profitability

EPS (Most Recent Fiscal Year)($0.83)
Net Income$-26,890,000.00
Net Margins-15.39%
Return on Equity-16.74%
Return on Assets-10.04%

Miscellaneous

Employees570
Outstanding Shares35,080,000

How to Become a New Pot Stock Millionaire

AtriCure (NASDAQ:ATRC) Frequently Asked Questions

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

How were AtriCure's earnings last quarter?

AtriCure (NASDAQ:ATRC) posted its quarterly earnings data on Monday, February, 26th. The medical device company reported ($0.08) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.21) by $0.13. The medical device company had revenue of $46.06 million for the quarter, compared to analysts' expectations of $45.85 million. AtriCure had a negative return on equity of 16.74% and a negative net margin of 15.39%. AtriCure's revenue was up 11.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.27) EPS. View AtriCure's Earnings History.

When is AtriCure's next earnings date?

AtriCure is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for AtriCure.

What price target have analysts set for ATRC?

5 Wall Street analysts have issued 12 month price targets for AtriCure's shares. Their predictions range from $23.00 to $26.00. On average, they anticipate AtriCure's share price to reach $24.80 in the next year. View Analyst Ratings for AtriCure.

What are Wall Street analysts saying about AtriCure stock?

Here are some recent quotes from research analysts about AtriCure stock:
  • 1. Needham & Company LLC analysts commented, "ATRC’s 4Q17 revenue was consistent with its 1/8/18 preannouncement while its EBITDA missed consensus and EPS beat consensus even excluding a $0.12 non-cash benefit. Management reiterated its 2018 revenue guidance of $190-196M vs. consensus of $195M. We believe the recent society guidelines, new products (AtriClip Pro-V and Flex-V), and surgeon training activities should drive strong growth. We believe that management’s more conservative guidance leaves room for upside and with ATRC shares trading at a large discount to peers (2018E EV/sales of 3.3x vs. small/mid-cap growth peers at a median of 6.4x), we reiterate our Buy rating." (2/27/2018)
  • 2. According to Zacks Investment Research, "AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart. " (10/2/2017)

Who are some of AtriCure's key competitors?

Who are AtriCure's key executives?

AtriCure's management team includes the folowing people:
  • Mr. Michael H. Carrel, Chief Exec. Officer, Pres and Director (Age 47)
  • Mr. M. Andrew Wade, Chief Financial Officer and Sr. VP (Age 43)
  • Mr. Douglas J. Seith, Chief Operating Officer (Age 52)
  • Mr. Justin J. Noznesky, Sr. VP of Marketing and Bus. Devel. (Age 40)
  • Mr. Karl Dahlquist, Chief Compliance Officer and VP of Legal & Compliance

Has AtriCure been receiving favorable news coverage?

Media coverage about ATRC stock has been trending somewhat positive recently, according to Accern. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. AtriCure earned a daily sentiment score of 0.13 on Accern's scale. They also gave news articles about the medical device company an impact score of 46.88 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of AtriCure?

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $21.21.

How big of a company is AtriCure?

AtriCure has a market capitalization of $748.19 million and generates $174.72 million in revenue each year. The medical device company earns $-26,890,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. AtriCure employs 570 workers across the globe.

How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.


MarketBeat Community Rating for AtriCure (ATRC)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  298 (Vote Outperform)
Underperform Votes:  166 (Vote Underperform)
Total Votes:  464
MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote "Outperform" if you believe ATRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AtriCure (NASDAQ:ATRC) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for AtriCure in the last 12 months. Their average twelve-month price target is $24.80, suggesting that the stock has a possible upside of 16.93%. The high price target for ATRC is $26.00 and the low price target for ATRC is $23.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.862.86
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $24.80$24.80$24.3333$25.8333
Price Target Upside: 16.93% upside35.37% upside37.24% upside10.21% upside

AtriCure (NASDAQ:ATRC) Consensus Price Target History

Price Target History for AtriCure (NASDAQ:ATRC)

AtriCure (NASDAQ:ATRC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/27/2018Canaccord GenuityBoost Price TargetBuy -> Buy$24.00 -> $26.00HighView Rating Details
2/27/2018Needham & Company LLCReiterated RatingBuy$23.00HighView Rating Details
12/10/2017Piper JaffrayReiterated RatingBuy$24.00LowView Rating Details
7/30/2017Stifel NicolausReiterated RatingBuy$25.00MediumView Rating Details
6/16/2017Leerink SwannReiterated RatingOutperform$26.00LowView Rating Details
3/20/2017Northland SecuritiesReiterated RatingBuy$24.00LowView Rating Details
3/6/2017BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
8/6/2016JMP SecuritiesSet Price TargetBuy$23.00N/AView Rating Details
8/5/2016UBSLower Price TargetSell$15.00 -> $14.00N/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

AtriCure (NASDAQ:ATRC) Earnings History and Estimates Chart

Earnings by Quarter for AtriCure (NASDAQ:ATRC)

AtriCure (NASDAQ:ATRC) Earnings Estimates

2018 EPS Consensus Estimate: ($0.87)
2019 EPS Consensus Estimate: ($0.63)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.29)($0.29)($0.29)
Q2 20181($0.27)($0.27)($0.27)
Q3 20181($0.18)($0.18)($0.18)
Q4 20181($0.13)($0.13)($0.13)
Q1 20191($0.24)($0.24)($0.24)
Q2 20191($0.21)($0.21)($0.21)
Q3 20191($0.12)($0.12)($0.12)
Q4 20191($0.06)($0.06)($0.06)

AtriCure (NASDAQ ATRC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018($0.27)N/AView Earnings Details
2/26/2018Q4 2017($0.21)($0.08)$45.85 million$46.06 millionViewListenView Earnings Details
11/1/2017Q3 2017($0.24)($0.22)$43.44 million$42.20 millionViewN/AView Earnings Details
7/27/2017Q2 2017($0.26)($0.2130)$44.15 million$45.23 millionViewN/AView Earnings Details
5/4/2017Q1 2017($0.33)($0.32)$40.25 million$41.30 millionViewListenView Earnings Details
2/28/2017Q4 2016($0.3180)($0.27)$41.17 million$41.20 millionViewListenView Earnings Details
10/27/2016Q316($0.28)($0.21)$10.75 million$38.34 millionViewListenView Earnings Details
8/4/2016Q216($0.30)($0.26)$39.84 million$39.70 millionViewListenView Earnings Details
4/28/2016Q116($0.32)($0.31)$36.08 million$35.90 millionViewListenView Earnings Details
2/23/2016Q415($0.36)($0.36)$35.90 million$35.90 millionViewListenView Earnings Details
10/27/2015Q315($0.22)($0.22)$31.32 million$31.40 millionViewListenView Earnings Details
7/28/2015Q215($0.21)($0.18)$30.51 million$32.58 millionViewListenView Earnings Details
4/29/2015Q115($0.21)($0.19)$28.65 million$29.90 millionViewListenView Earnings Details
2/23/2015Q414($0.20)($0.20)$28.40 million$29.40 millionViewListenView Earnings Details
10/30/2014Q314($0.17)($0.02)$25.60 million$26.70 millionViewListenView Earnings Details
7/24/2014Q214($0.19)($0.10)$25.03 million$26.51 millionViewListenView Earnings Details
4/24/2014Q114($0.22)($0.31)$23.36 million$24.80 millionViewListenView Earnings Details
2/27/2014Q413($0.14)($0.24)$21.16 million$21.90 millionViewListenView Earnings Details
10/29/2013Q313($0.15)($0.13)$18.30 million$20.10 millionViewListenView Earnings Details
8/1/2013Q2 2013($0.10)($0.09)$19.42 million$20.40 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.09)($0.10)$18.63 million$19.43 millionViewListenView Earnings Details
2/28/2013Q4 2012($0.09)($0.12)$18.46 million$18.40 millionViewListenView Earnings Details
11/1/2012Q312($0.11)($0.16)$17.29 million$16.10 millionViewN/AView Earnings Details
8/2/2012($0.07)($0.08)ViewN/AView Earnings Details
5/2/2012($0.13)($0.10)ViewN/AView Earnings Details
2/27/2012Q4 2011($0.07)($0.13)ViewN/AView Earnings Details
11/1/2011($0.07)($0.07)ViewN/AView Earnings Details
8/2/2011($0.01)($0.06)ViewN/AView Earnings Details
5/4/2011Q1 2011($0.07)($0.08)ViewN/AView Earnings Details
11/2/2010Q3 2010($0.10)($0.07)ViewN/AView Earnings Details
8/4/2010Q2 2010($0.12)($0.05)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.09)($0.13)ViewN/AView Earnings Details
2/18/2010Q4 2009($0.09)($0.15)ViewN/AView Earnings Details
11/4/2009Q3 2009($0.09)($0.06)ViewN/AView Earnings Details
8/4/2009Q2 2009($0.08)($0.08)ViewN/AView Earnings Details
5/5/2009Q1 2009($0.18)($0.08)ViewN/AView Earnings Details
2/19/2009Q4 2008($0.16)($0.16)ViewN/AView Earnings Details
11/4/2008Q3 2008($0.16)($0.12)ViewN/AView Earnings Details
8/5/2008Q2 2008($0.18)($0.11)ViewN/AView Earnings Details
5/6/2008Q1 2008($0.23)($0.25)ViewN/AView Earnings Details
2/14/2008Q4 2007($0.20)($0.11)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

AtriCure (NASDAQ:ATRC) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

AtriCure (NASDAQ ATRC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 87.70%
Insider Trading History for AtriCure (NASDAQ:ATRC)
Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)

AtriCure (NASDAQ ATRC) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/13/2018Elizabeth D KrellDirectorSell10,000$20.00$200,000.00View SEC Filing  
3/1/2018Regina E GrovesDirectorBuy1,000$17.43$17,430.00View SEC Filing  
2/15/2018Justin J NozneskySVPSell4,000$17.03$68,120.00View SEC Filing  
11/30/2017M. Andrew WadeCFOSell2,000$18.41$36,820.00View SEC Filing  
11/8/2017B Kristine JohnsonDirectorBuy1,500$18.36$27,540.0010,969View SEC Filing  
8/22/2017Elizabeth D KrellDirectorSell10,000$22.40$224,000.0029,967View SEC Filing  
5/17/2017Elizabeth D KrellDirectorSell10,000$21.44$214,400.0024,162View SEC Filing  
3/17/2017Andrew L LuxSVPSell20,000$18.85$377,000.0085,589View SEC Filing  
11/15/2016Elizabeth D KrellDirectorSell10,000$19.73$197,300.0024,162View SEC Filing  
9/13/2016Elizabeth D KrellDirectorSell6,000$15.93$95,580.0020,162View SEC Filing  
8/17/2016Elizabeth D KrellDirectorSell5,000$15.20$76,000.0015,162View SEC Filing  
3/8/2016Elizabeth D KrellDirectorSell10,000$16.91$169,100.0017,162View SEC Filing  
12/3/2015Douglas J. SeithCOOSell5,000$21.55$107,750.00125,215View SEC Filing  
12/2/2015Elizabeth D. KrellDirectorSell10,000$21.88$218,800.007,162View SEC Filing  
11/11/2015Elizabeth D. KrellDirectorSell10,000$20.68$206,800.007,162View SEC Filing  
4/1/2015Michael D HoovenDirectorSell142,268$20.81$2,960,597.08View SEC Filing  
3/31/2015Michael D HoovenDirectorSell20,000$20.51$410,200.00View SEC Filing  
3/30/2015Michael D HoovenDirectorSell85,000$21.01$1,785,850.00View SEC Filing  
3/13/2015Karen P RobardsDirectorSell3,150$19.53$61,519.50View SEC Filing  
3/5/2015Douglas J SeithCOOSell36,688$17.51$642,406.88View SEC Filing  
3/2/2015Elizabeth D KrellDirectorSell10,000$17.63$176,300.00View SEC Filing  
5/6/2014Douglas SeithSVPBuy1,000$15.04$15,040.0095,694View SEC Filing  
9/13/2013Richard JohnstonInsiderSell77,610$10.00$776,100.00View SEC Filing  
8/12/2013Douglas SeithSVPBuy10,000$9.58$95,800.0058,240View SEC Filing  
8/5/2013Richard JohnstonInsiderSell20,047$10.00$200,470.00View SEC Filing  
7/11/2013Richard M JohnstonInsiderSell2,343$10.00$23,430.00View SEC Filing  
6/19/2013Richard M JohnstonInsiderSell29,348$8.96$262,958.08View SEC Filing  
6/18/2013Richard M JohnstonInsiderSell39,682$9.18$364,280.76View SEC Filing  
6/14/2013Richard M JohnstonInsiderSell95,598$8.97$857,514.06View SEC Filing  
6/12/2013Richard M JohnstonInsiderSell35,372$9.01$318,701.72View SEC Filing  
3/6/2013James L LuckyVPSell50,065$8.14$407,529.10View SEC Filing  
9/14/2012Mark R LanningDirectorBuy11,006$7.64$84,085.84View SEC Filing  
9/13/2012Michael D HoovenDirectorBuy1,110$7.37$8,180.70View SEC Filing  
9/12/2012Michael D HoovenDirectorBuy1,150$7.10$8,165.00View SEC Filing  
9/11/2012Michael D HoovenDirectorBuy1,145$7.18$8,221.10View SEC Filing  
9/10/2012Michael D HoovenDirectorBuy1,215$7.15$8,687.25View SEC Filing  
9/7/2012Michael D HoovenDirectorBuy1,215$6.88$8,359.20View SEC Filing  
8/23/2012Karen P RobardsDirectorBuy1,000$6.70$6,700.00View SEC Filing  
8/16/2012Karen P RobardsDirectorBuy1,000$6.98$6,980.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AtriCure (NASDAQ ATRC) News Headlines

Source:
DateHeadline
AtriCure (ATRC) Expected to Announce Quarterly Sales of $45.77 MillionAtriCure (ATRC) Expected to Announce Quarterly Sales of $45.77 Million
www.americanbankingnews.com - April 21 at 4:20 AM
AtriCure (ATRC) Expected to Announce Earnings of -$0.26 Per ShareAtriCure (ATRC) Expected to Announce Earnings of -$0.26 Per Share
www.americanbankingnews.com - April 19 at 9:51 AM
BidaskClub Downgrades AtriCure (ATRC) to BuyBidaskClub Downgrades AtriCure (ATRC) to Buy
www.americanbankingnews.com - April 16 at 7:00 PM
Is There Now An Opportunity In AtriCure Inc (NASDAQ:ATRC)?Is There Now An Opportunity In AtriCure Inc (NASDAQ:ATRC)?
finance.yahoo.com - April 10 at 5:47 PM
Free Post Earnings Research Report: AtriCure’s Quarterly Revenues Jumped 11.9%; Net Loss NarrowedFree Post Earnings Research Report: AtriCure’s Quarterly Revenues Jumped 11.9%; Net Loss Narrowed
finance.yahoo.com - April 9 at 8:22 AM
AtriCure Inc. (ATRC) Expected to Post Quarterly Sales of $45.77 MillionAtriCure Inc. (ATRC) Expected to Post Quarterly Sales of $45.77 Million
www.americanbankingnews.com - April 4 at 3:58 AM
-$0.26 EPS Expected for AtriCure Inc. (ATRC) This Quarter-$0.26 EPS Expected for AtriCure Inc. (ATRC) This Quarter
www.americanbankingnews.com - April 2 at 9:12 AM
AtriCure (ATRC) Given New $25.00 Price Target at Needham & Company LLCAtriCure (ATRC) Given New $25.00 Price Target at Needham & Company LLC
www.americanbankingnews.com - April 2 at 8:39 AM
AtriCure (ATRC) Given New $24.00 Price Target at Canaccord GenuityAtriCure (ATRC) Given New $24.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - April 1 at 10:52 PM
AtriCure Inc. (ATRC) Given Average Rating of "Buy" by BrokeragesAtriCure Inc. (ATRC) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 1 at 9:36 AM
AtriCures (ATRC) Buy Rating Reiterated at Needham & Company LLCAtriCure's (ATRC) Buy Rating Reiterated at Needham & Company LLC
www.americanbankingnews.com - March 28 at 2:06 PM
AtriCure (ATRC) Given New $26.00 Price Target at Canaccord GenuityAtriCure (ATRC) Given New $26.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - March 24 at 9:30 PM
AtriCure (ATRC) Upgraded at TheStreetAtriCure (ATRC) Upgraded at TheStreet
www.americanbankingnews.com - March 24 at 12:28 AM
AtriCure (ATRC) versus Rockwell Medical (RMTI) Critical ComparisonAtriCure (ATRC) versus Rockwell Medical (RMTI) Critical Comparison
www.americanbankingnews.com - March 20 at 3:19 AM
AtriCure (ATRC) Upgraded at BidaskClubAtriCure (ATRC) Upgraded at BidaskClub
www.americanbankingnews.com - March 17 at 3:54 PM
Zacks: Analysts Expect AtriCure Inc. (ATRC) Will Announce Earnings of -$0.26 Per ShareZacks: Analysts Expect AtriCure Inc. (ATRC) Will Announce Earnings of -$0.26 Per Share
www.americanbankingnews.com - March 16 at 7:33 AM
AtriCure to Present at the Needham & Company’s 17th Annual Healthcare ConferenceAtriCure to Present at the Needham & Company’s 17th Annual Healthcare Conference
finance.yahoo.com - March 15 at 9:12 AM
Elizabeth D. Krell Sells 10,000 Shares of AtriCure Inc. (ATRC) StockElizabeth D. Krell Sells 10,000 Shares of AtriCure Inc. (ATRC) Stock
www.americanbankingnews.com - March 14 at 7:49 PM
SeaSpine (SPNE) & AtriCure (ATRC) Head to Head ReviewSeaSpine (SPNE) & AtriCure (ATRC) Head to Head Review
www.americanbankingnews.com - March 12 at 3:10 AM
Meridian Bioscience (VIVO) versus AtriCure (ATRC) Head-To-Head ReviewMeridian Bioscience (VIVO) versus AtriCure (ATRC) Head-To-Head Review
www.americanbankingnews.com - March 10 at 4:18 PM
Active-Investors: Free Research Report as ConforMIS Reported Better Than Expected ResultsActive-Investors: Free Research Report as ConforMIS Reported Better Than Expected Results
www.finanznachrichten.de - March 9 at 9:21 AM
Free Research Report as ConforMIS Reported Better Than Expected ResultsFree Research Report as ConforMIS Reported Better Than Expected Results
finance.yahoo.com - March 9 at 9:21 AM
AtriCure Inc. (ATRC) Given Average Recommendation of "Buy" by BrokeragesAtriCure Inc. (ATRC) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 7 at 2:02 PM
AtriCure Inc. (ATRC) Position Raised by Tamarack Advisers LPAtriCure Inc. (ATRC) Position Raised by Tamarack Advisers LP
www.americanbankingnews.com - March 6 at 10:30 AM
Royce & Associates LP Increases Holdings in AtriCure Inc. (ATRC)Royce & Associates LP Increases Holdings in AtriCure Inc. (ATRC)
www.americanbankingnews.com - March 2 at 10:44 AM
Report: Developing Opportunities within LCI Industries, Biglari, Graco, Federal Signal, AtriCure, and Perry Ellis International — Future Expectations, Projections Moving into 2018Report: Developing Opportunities within LCI Industries, Biglari, Graco, Federal Signal, AtriCure, and Perry Ellis International — Future Expectations, Projections Moving into 2018
finance.yahoo.com - March 2 at 8:09 AM
Regina E. Groves Acquires 1,000 Shares of AtriCure Inc. (ATRC) StockRegina E. Groves Acquires 1,000 Shares of AtriCure Inc. (ATRC) Stock
www.americanbankingnews.com - March 1 at 10:44 PM
$46.55 Million in Sales Expected for AtriCure Inc. (ATRC) This Quarter$46.55 Million in Sales Expected for AtriCure Inc. (ATRC) This Quarter
www.americanbankingnews.com - March 1 at 8:58 AM
AtriCure Inc. (ATRC) Expected to Earn Q1 2018 Earnings of ($0.29) Per ShareAtriCure Inc. (ATRC) Expected to Earn Q1 2018 Earnings of ($0.29) Per Share
www.americanbankingnews.com - March 1 at 8:36 AM
AtriCure Inc (ATRC) Files 10-K for the Fiscal Year Ended on December 31, 2017AtriCure Inc (ATRC) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - March 1 at 8:22 AM
AtriCure Inc. to Post FY2022 Earnings of $0.22 Per Share, Leerink Swann Forecasts (ATRC)AtriCure Inc. to Post FY2022 Earnings of $0.22 Per Share, Leerink Swann Forecasts (ATRC)
www.americanbankingnews.com - February 28 at 4:51 PM
AtriCure Inc. (ATRC) Shares Sold by Cortina Asset Management LLCAtriCure Inc. (ATRC) Shares Sold by Cortina Asset Management LLC
www.americanbankingnews.com - February 28 at 1:27 PM
AtriCures (ATRC) CEO Mike Carrel on Q4 2017 Results - Earnings Call TranscriptAtriCure's (ATRC) CEO Mike Carrel on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - February 27 at 5:52 PM
AtriCure (ATRC) Issues Quarterly  Earnings ResultsAtriCure (ATRC) Issues Quarterly Earnings Results
www.americanbankingnews.com - February 27 at 9:46 AM
AtriCure (ATRC) Stock Rating Reaffirmed by Needham & Company LLCAtriCure (ATRC) Stock Rating Reaffirmed by Needham & Company LLC
www.americanbankingnews.com - February 27 at 8:22 AM
AtriCure, Inc. to Host Earnings CallAtriCure, Inc. to Host Earnings Call
finance.yahoo.com - February 26 at 5:43 PM
AtriCure Reports Fourth Quarter and Full Year 2017 Financial ResultsAtriCure Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 26 at 5:43 PM
AtriCure Q4 Earnings OutlookAtriCure Q4 Earnings Outlook
feeds.benzinga.com - February 26 at 12:16 PM
AlphaOne Investment Services LLC Has $4.19 Million Stake in AtriCure Inc. (ATRC)AlphaOne Investment Services LLC Has $4.19 Million Stake in AtriCure Inc. (ATRC)
www.americanbankingnews.com - February 26 at 5:14 AM
BidaskClub Upgrades AtriCure (ATRC) to HoldBidaskClub Upgrades AtriCure (ATRC) to Hold
www.americanbankingnews.com - February 25 at 12:00 AM
Neurometrix (NURO) vs. AtriCure (ATRC) Critical ReviewNeurometrix (NURO) vs. AtriCure (ATRC) Critical Review
www.americanbankingnews.com - February 24 at 9:18 AM
AtriCure Launches the AtriClip® FLEX•V™ Device in the United StatesAtriCure Launches the AtriClip® FLEX•V™ Device in the United States
finance.yahoo.com - February 22 at 8:02 AM
Cincinnati medical device maker gets board refreshCincinnati medical device maker gets board refresh
finance.yahoo.com - February 20 at 5:43 PM
AtriCure Names Scott Drake Board ChairmanAtriCure Names Scott Drake Board Chairman
finance.yahoo.com - February 20 at 8:03 AM
AtriCure (ATRC) to Release Earnings on MondayAtriCure (ATRC) to Release Earnings on Monday
www.americanbankingnews.com - February 19 at 3:46 AM
AtriCure (ATRC) Upgraded to Sell at BidaskClubAtriCure (ATRC) Upgraded to Sell at BidaskClub
www.americanbankingnews.com - February 17 at 11:36 PM
AtriCure Inc. (ATRC) SVP Justin J. Noznesky Sells 4,000 SharesAtriCure Inc. (ATRC) SVP Justin J. Noznesky Sells 4,000 Shares
www.americanbankingnews.com - February 16 at 10:20 PM
AtriCure Inc. (ATRC) Expected to Post Quarterly Sales of $45.45 MillionAtriCure Inc. (ATRC) Expected to Post Quarterly Sales of $45.45 Million
www.americanbankingnews.com - February 12 at 3:56 AM
-$0.21 Earnings Per Share Expected for AtriCure Inc. (ATRC) This Quarter-$0.21 Earnings Per Share Expected for AtriCure Inc. (ATRC) This Quarter
www.americanbankingnews.com - February 10 at 3:12 PM
AtriCure Inc. (ATRC) Given Consensus Recommendation of "Hold" by AnalystsAtriCure Inc. (ATRC) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 10 at 12:58 PM

SEC Filings

AtriCure (NASDAQ:ATRC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AtriCure (NASDAQ:ATRC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AtriCure (NASDAQ ATRC) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.